These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
512 related articles for article (PubMed ID: 27693350)
1. Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells. Boice M; Salloum D; Mourcin F; Sanghvi V; Amin R; Oricchio E; Jiang M; Mottok A; Denis-Lagache N; Ciriello G; Tam W; Teruya-Feldstein J; de Stanchina E; Chan WC; Malek SN; Ennishi D; Brentjens RJ; Gascoyne RD; Cogné M; Tarte K; Wendel HG Cell; 2016 Oct; 167(2):405-418.e13. PubMed ID: 27693350 [TBL] [Abstract][Full Text] [Related]
2. A herpesvirus entry mediator mutein with selective agonist action for the inhibitory receptor B and T lymphocyte attenuator. Šedý JR; Balmert MO; Ware BC; Smith W; Nemčovičova I; Norris PS; Miller BR; Aivazian D; Ware CF J Biol Chem; 2017 Dec; 292(51):21060-21070. PubMed ID: 29061848 [TBL] [Abstract][Full Text] [Related]
3. The HVEM-BTLA Axis Restrains T Cell Help to Germinal Center B Cells and Functions as a Cell-Extrinsic Suppressor in Lymphomagenesis. Mintz MA; Felce JH; Chou MY; Mayya V; Xu Y; Shui JW; An J; Li Z; Marson A; Okada T; Ware CF; Kronenberg M; Dustin ML; Cyster JG Immunity; 2019 Aug; 51(2):310-323.e7. PubMed ID: 31204070 [TBL] [Abstract][Full Text] [Related]
4. High expression of the inhibitory receptor BTLA in T-follicular helper cells and in B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia. M'Hidi H; Thibult ML; Chetaille B; Rey F; Bouadallah R; Nicollas R; Olive D; Xerri L Am J Clin Pathol; 2009 Oct; 132(4):589-96. PubMed ID: 19762537 [TBL] [Abstract][Full Text] [Related]
5. The BTLA-HVEM axis restricts CAR T cell efficacy in cancer. Guruprasad P; Carturan A; Zhang Y; Cho JH; Kumashie KG; Patel RP; Kim KH; Lee JS; Lee Y; Kim JH; Chung J; Joshi A; Cohen I; Shestov M; Ghilardi G; Harris J; Pajarillo R; Angelos M; Lee YG; Liu S; Rodriguez J; Wang M; Ballard HJ; Gupta A; Ugwuanyi OH; Hong SJA; Bochi-Layec AC; Sauter CT; Chen L; Paruzzo L; Kammerman S; Shestova O; Liu D; Vella LA; Schuster SJ; Svoboda J; Porazzi P; Ruella M Nat Immunol; 2024 Jun; 25(6):1020-1032. PubMed ID: 38831106 [TBL] [Abstract][Full Text] [Related]
6. T cell intrinsic heterodimeric complexes between HVEM and BTLA determine receptivity to the surrounding microenvironment. Cheung TC; Oborne LM; Steinberg MW; Macauley MG; Fukuyama S; Sanjo H; D'Souza C; Norris PS; Pfeffer K; Murphy KM; Kronenberg M; Spear PG; Ware CF J Immunol; 2009 Dec; 183(11):7286-96. PubMed ID: 19915044 [TBL] [Abstract][Full Text] [Related]
7. T follicular helper expansion and humoral-mediated rejection are independent of the HVEM/BTLA pathway. Rodriguez-Barbosa JI; Fernandez-Renedo C; Moral AMB; Bühler L; Del Rio ML Cell Mol Immunol; 2017 Jun; 14(6):497-510. PubMed ID: 26924526 [TBL] [Abstract][Full Text] [Related]
8. Molecular basis for herpesvirus entry mediator recognition by the human immune inhibitory receptor CD160 and its relationship to the cosignaling molecules BTLA and LIGHT. Kojima R; Kajikawa M; Shiroishi M; Kuroki K; Maenaka K J Mol Biol; 2011 Nov; 413(4):762-72. PubMed ID: 21959263 [TBL] [Abstract][Full Text] [Related]
9. High TNFRSF14 and low BTLA are associated with poor prognosis in Follicular Lymphoma and in Diffuse Large B-cell Lymphoma transformation. Carreras J; Lopez-Guillermo A; Kikuti YY; Itoh J; Masashi M; Ikoma H; Tomita S; Hiraiwa S; Hamoudi R; Rosenwald A; Leich E; Martinez A; Roncador G; Villamor N; Colomo L; Perez P; Tsuji NM; Campo E; Nakamura N J Clin Exp Hematop; 2019; 59(1):1-16. PubMed ID: 30918139 [TBL] [Abstract][Full Text] [Related]
10. Design of short peptides to block BTLA/HVEM interactions for promoting anticancer T-cell responses. Spodzieja M; Lach S; Iwaszkiewicz J; Cesson V; Kalejta K; Olive D; Michielin O; Speiser DE; Zoete V; Derré L; Rodziewicz-Motowidło S PLoS One; 2017; 12(6):e0179201. PubMed ID: 28594868 [TBL] [Abstract][Full Text] [Related]
11. [Therapeutic effects of B and T lymphocyte attenuator extracellular domain and heat shock protein 70 antigen peptide on cervical cancer in mouse model]. Han LF; Qiu WM; Hu C; Wang L; Yao HX; Xiong SY; Meng M; Fang Y; Ma D Zhonghua Fu Chan Ke Za Zhi; 2010 Aug; 45(8):603-8. PubMed ID: 21029617 [TBL] [Abstract][Full Text] [Related]
13. Regulatory T cell expression of herpesvirus entry mediator suppresses the function of B and T lymphocyte attenuator-positive effector T cells. Tao R; Wang L; Murphy KM; Fraser CC; Hancock WW J Immunol; 2008 May; 180(10):6649-55. PubMed ID: 18453584 [TBL] [Abstract][Full Text] [Related]
14. HVEM network signaling in cancer. Šedý JR; Ramezani-Rad P Adv Cancer Res; 2019; 142():145-186. PubMed ID: 30885361 [TBL] [Abstract][Full Text] [Related]
15. T Cells Expressing CAR Equipped With Extracellular Domain of BTLA Are Effective Against HVEM-over-expressing Melanoma Cell Lines. Kim Y; Kim JE; Lee DY; Choi JU; Park JS; Lee HK; Choi SU; Park S; Park CH Anticancer Res; 2023 Aug; 43(8):3419-3427. PubMed ID: 37500142 [TBL] [Abstract][Full Text] [Related]
16. A T Cell-B Cell Tumor-Suppressive Axis in the Germinal Center. Kennedy R; Klein U Immunity; 2019 Aug; 51(2):204-206. PubMed ID: 31433965 [TBL] [Abstract][Full Text] [Related]
17. Disulfide-Linked Peptides for Blocking BTLA/HVEM Binding. Spodzieja M; Kuncewicz K; Sieradzan A; Karczyńska A; Iwaszkiewicz J; Cesson V; Węgrzyn K; Zhukov I; Maszota-Zieleniak M; Michielin O; Speiser DE; Zoete V; Derré L; Rodziewicz-Motowidło S Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963646 [TBL] [Abstract][Full Text] [Related]
19. BTLA inhibition has a dominant role in the Battin C; Leitner J; Waidhofer-Söllner P; Grabmeier-Pfistershammer K; Olive D; Steinberger P Front Immunol; 2022; 13():956694. PubMed ID: 36081508 [TBL] [Abstract][Full Text] [Related]